Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.25

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.25), versus ($0.39) reported last year. Revenue for the quarter came in at $400 thousand, versus $200 thousand reported last year.

Cash Position: Cash and cash equivalents were $20.3 million as of March 31, 2017, compared to $25.3 million as of December 31, 2016.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc eyes US banking license as next business step
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance